Anti-PD-L1 / B7-H1 / CD274, clone MSVA-711R

Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide. Programmed death-ligand 1 (CD274), commonly known as PD-L1, is an immune checkpoint protein expressed on tumor cells and antigen-presenting cells that regulates T cell activation through interaction with PD-1. PD-L1 Antibody for IHC / CD274 Immunohistochemistry Antibody is widely used to evaluate immune checkpoint signaling and tumor-associated immune evasion in formalin-fixed, paraffin-embedded tissues. Its expression within tumor and immune cell populations makes it a central marker for studying the tumor microenvironment and immune regulation.PD-L1 antibody, also referred to as CD274 antibody or B7-H1 antibody, produces characteristic membranous staining in tumor cells and tumor-infiltrating immune cells, with occasional cytoplasmic signal depending on protein turnover and cellular context. In immunohistochemistry, PD-L1 staining is observed across a wide range of malignancies including lung carcinoma, melanoma, renal cell carcinoma, and other solid tumors, as well as in macrophages and lymphocytes within the tumor stroma. Tissue microarray (TMA) analysis highlights heterogeneous but biologically consistent staining patterns across cancer tissue panels, reflecting variable expression within and between tumor types.Tissue microarray-based immunohistochemistry provides a powerful platform for comparing PD-L1 expression across normal and malignant tissues under standardized staining conditions. Across TMA panels, PD-L1 staining reveals distinct membranous labeling of tumor cells alongside variable staining of immune infiltrates, enabling assessment of tumor immune context and spatial distribution of checkpoint expression. Most normal tissues demonstrate limited or inducible expression, typically confined to immune-related cell populations, creating clear contrast between physiologic expression and tumor-associated upregulation.In cancer research and diagnostic applications, PD-L1 immunohistochemistry is extensively used to characterize immune checkpoint status and to stratify tumors based on their interaction with the immune system. The presence, intensity, and localization of PD-L1 staining, particularly membranous expression on tumor cells, are critical parameters for evaluating immune evasion mechanisms and for correlating with responsiveness to checkpoint blockade therapies.PD-L1 is a type I transmembrane protein belonging to the B7 family of immune regulatory ligands and is primarily localized to the cell membrane. Its expression is dynamically regulated by inflammatory signals such as interferon-gamma, linking immune activation to checkpoint-mediated suppression. This inducible expression pattern contributes to the complex and heterogeneous staining observed across tissue microarray panels.Overall, PD-L1 Antibody for IHC enables robust detection of CD274 expression with clear membranous staining patterns and reproducible performance across tissue microarray panels. Its consistent detection of tumor and immune cell expression supports its use in immunohistochemistry for tumor characterization, immune profiling, and evaluation of the tumor microenvironment.This antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.